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Human immunodeficiency virus type 1 (HIV-1) viral proteins disrupt the normal host cellular immune pathways thus exploiting the cellular
machinery for replication, survival and to escape host immune attack. Here we evaluated the direct effects of HIV-1 Vpr-mediated immune
modulation of infected T cells. Vpr specifically downregulated the expression of CD28 and increased the expression of CTLA-4, whereas no
significant difference in the expression of CD25 and HLA-DR was observed. Interferon gamma (IFN-γ) production in T cells was evaluated as a
measure of the downstream effector functions. Results indicate that Vpr significantly inhibited IFN-γ production and this may, in part, due to
Vpr's ability to inhibit the nuclear translocation of NF-κB, and its transcriptional regulation. Together these results support that HIV-1 Vpr
selectively dysregulates the immune functions at multiple levels and exerts its inhibitory effects in the presence of other viral proteins.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV-1 Vpr; CD28; CTLA-4; IFN-γ; NF-κB; Immune activationIntroduction
Costimulatory molecules expressed in T cells provide the
second signal required for optimum activation and differentia-
tion of T lymphocytes upon antigen recognition (Inaba and
Inaba, 2005; Oh et al., 2003). CD28 and CTLA-4 are the main
costimulatory molecules in T cells that interact with CD80 and
CD86 on the antigen presenting cells (APC) and initiate
proliferation, differentiation and effector functions (Giannoni et
al., 2005; Melief, 2003; Riley and June, 2005). Expression of
CD28 molecules increases following specific antigen recogni-
tion through TCR and acts as the positive regulator of the T cell
signaling cascade. In contrast, CTLA-4, a CD28 homolog,
negatively regulates the effects of TCR signaling (Magott-
Procelewska, 2004; Perkins et al., 1996). The effectiveness of
the immune response, including the secretion of cytokines, is
controlled by the interaction of CD28 and CTLA-4 with their⁎ Corresponding author. Fax: +1 412 624 5612.
E-mail address: velpandi@pitt.edu (V. Ayyavoo).
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doi:10.1016/j.virol.2006.08.030ligands on the APC. Therefore, differential expression of these
important molecules can skew the outcome of the immune
response. Dysregulation of CD28 and CTLA-4 in T lympho-
cytes has been well documented in HIV-1-infected patients and
is directly correlated with disease progression (Leng et al.,
2002; Riley et al., 2000; Steiner et al., 1999; Stone et al., 2005).
Additionally, signaling through CTLA-4 is documented to
counteract CD28-mediated anti-HIV-1 effects and facilitate the
replication of the virus and enhance the susceptibility of
neighboring cells (Riley et al., 2000).
HIV-1 exploits various mechanisms to modulate the function
of important cellular molecules in T lymphocytes at multiple
levels. HIV-1 Nef protein is involved in accelerating the
endocytosis of CD4, CD28 and MHC class I molecules (Aiken
et al., 1994; Stove et al., 2005; Williams et al., 2002), whereas,
the vpu gene product has been reported to affect the biosynthesis
of MHC class I molecules and cause ubiquitination-dependent
degradation of CD4 molecules in infected T lymphocytes
(Levesque et al., 2003; Willey et al., 1992). The ability of Env,
Nef and Vpu to disrupt the expression of CD4 molecules in
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proteins disrupt the normal host cellular immune pathways in T
lymphocytes thus exploiting the cellular machinery for viral
replication and survival (Anderson and Hope, 2004; Collins and
Baltimore, 1999; Li et al., 2005; Speth and Dierich, 1999).
HIV-1 vpr gene encodes a 96-amino-acid protein that is
incorporated into the virus particle through its interaction with
p6 subunit of Gag, thus making Vpr as one of the first viral
proteins that the infected cells are exposed to, prior to de novo
synthesis (Bachand et al., 1999; Hrimech et al., 1999;
Tungaturthi et al., 2003). Patients infected with HIV-1 encoding
defects in Vpr have slower progression to AIDS (Lum et al.,
2003; Saksena et al., 1996; Wang et al., 1996). Vpr was shown
to dysregulate major immune pathways including antigen
presentation, cytokine network and T cell activation, by
impairing dendritic cell function as antigen presenting cells
(APC) (Majumder et al., 2005; Muthumani et al., 2005).
However, the direct effect of Vpr in infected T cells and its
immune functions are not clearly understood. Using enhanced
green florescence protein (EGFP) coding reporter viruses, with
and without vpr, here we evaluated the effect of HIV-1 Vpr on T
cell costimulatory molecules, CD28 and CTLA-4, as well as the
functional consequences of Vpr expression in T cell activation
in both infected and bystander cells. Results indicate that HIV-1
Vpr differentially regulated the expression of cell surface
molecules and impaired IFN-γ production that is involved in T
cell activation functions. Additionally, HIV-1 Vpr inhibited the
nuclear translocation of NF-κB in infected T cells. Together,
these results suggest that Vpr can selectively alter various
immune regulatory molecules at multiple levels in infected T
lymphocytes to escape host immune response.
Results
Construction and characterization of HIV-1 vpr(+) and HIV-1
vpr(−) EGFP reporter viruses
To clearly distinguish the role of HIV-1 Vpr on infected and
uninfected T cell immune functions, and to further understand
the contribution of Vpr in immunopathogenesis, EGFP reporter
viruses were constructed. This was achieved by the insertion of
EGFP reporter and IRES fragment in frame with the nef open
reading frame, which maintained the Nef expression (Fig. S1A).
To determine the expression of viral proteins, PBL were
infected as described in Materials and methods. Three days post
infection cells were lysed, and lysates were analyzed for
expression of Gag (p24), Nef and Vpr by immunoblot (Fig.
S1B). Immunoblot analysis indicates the expression of viral
proteins confirming the integrity of these constructs. Addition-Fig. 1. Differential regulation of T cell costimulatory molecules by HIV-1 Vpr: (A) P
Four days post infection the percentage of infected cells was analyzed by flow cytom
The CD3 expressing cells were then gated, and the Infected (EGFP+) and Bystande
CD28 was analyzed by flow cytometry using directly conjugated specific antibodi
expression of CD28 was analyzed on the infected (EGFP+) and bystander (EGFP−) c
derived using paired t test analysis comparing HIV-1 vpr(+) and HIV-1 vpr(−) grou
stained for surface and intracellular expression of CTLA-4 as described in Materials a
multiple donors (N=7). p value was evaluated by paired t test analysis.ally, function of Nef was evaluated by assessing the ability of
Nef to downregulate MHC I molecules in the infected T cells.
Viruses generated from 293T cells were used to infect Jurkat
JJK cells and the expression of MHC I and CD3 was tested by
flow cytometry (Fig. S1C). As a control, pNL43ΔNef/EGFP
(kind gift from Dr. David N. Levy, University of Alabama) was
used. Results indicate that both the HIV-1 vpr(+)/EGFP and
HIV-1 vpr(−)/EGFP constructs downregulated the expression of
MHC I in the infected cells (>40%), compared to the HIV-
1ΔNef/EGFP virus (<2%), indicating that both the expression
and function of Nef were maintained in these constructs. EGFP
expression was also evaluated by immunofluorescence micro-
scopy, and the ability of this reporter virus to distinctly identify
the infect cells was confirmed by flow cytometry (Fig. 1A).
Next, to confirm that the insertion of the IRES-EGFP
fragment into the NL43 viral genome did not impair its
replication competence, anti-CD3/anti-CD28-stimulated nor-
mal human PBL were infected, and virus replication was
monitored. Both viruses infected PBL efficiently and supported
virus replication, as measured by p24 production (Fig. S1D).
However, in the presence of Vpr, there was a slight increase in
the p24 levels in the HIV-1 vpr(+)/EGFP virus, compared to the
Vpr-negative counterpart, as observed before (Jeeninga et al.,
2005; Levy et al., 1995). Together these results indicate that
insertion of EGFP-IRES fragment did not alter either the
expression or the function of Nef, further confirming the
specific effects of Vpr in the presence of other viral proteins.
HIV-1 Vpr differentially regulates the expression of
costimulatory molecules CD28 and CTLA-4 in T cells
To determine the effect of HIV-1 Vpr costimulatory
molecules CD28 and CTLA-4 in vitro and its functional impact
on host immune responses, monocyte-depleted PBL (>95% as
measured by flow cytometry) were activated with anti-CD3 and
anti-CD28 antibody and infected with 0.01 MOI of HIV-1 vpr
(+)/EGFP or HIV-1 vpr(−)/EGFP virus. Four days post
infection, expressions of CD28, CTLA-4, CD25, and HLA-
DR were evaluated by flow cytometry. To distinguish the Vpr-
mediated effects in infected and bystander cells, cells were first
gated based on forward and side scatter, followed by gating on
CD3-positive cells. Within the CD3-positive cells, infected and
bystander cells were separated based on EGFP positivity.
Results indicate that there is no significant difference in the
number of cells (shown in percent positive) infected with either
HIV-1 vpr(+) or HIV-1 vpr(−) virus (Fig. 1A). Using this gating,
expression of CD28 was assessed in both EGFP-positive and
EGFP-negative cells. In HIV-1 vpr(+)-infected cells (consider-
ing the EGFP-positive as 100%), the number of cells expressingBL were infected with HIV-1 vpr(+)/EGFP or HIV-1 vpr(−)/EGFP as described.
etry. Viable lymphocytes were gated based on side and forward scatter dot plot.
r (EGFP−) cells were identified based on EGFP expression. (B) Expression of
es and isotype controls. The cells were gated as described in panel A, and the
ells. (C) Downregulation of CD28 by Vpr in multiple donors (N=7). p value was
ps. (D) Expression of CTLA-4 was determined by flow cytometry. Cells were
nd methods. (E) HIV-1 Vpr differentially regulates the expression of CTLA-4 in
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1 vpr(−)-virus-infected cells (94.2%), whereas no significant
change was observed in the bystander/uninfected cells (92.1
versus 94.5; Fig. 1B). Additionally the level of expression of
CD28, as measured by mean fluorescence intensity (MFI), was
also lower in the HIV-1 vpr(+)-virus-infected cells (143)
compared to the HIV-1 vpr(−)-virus-infected cells (239).
These studies were performed in PBL isolated from multiple
donors (N=7) and similar reduction was observed (Fig. 1C)
indicating that HIV-1 Vpr significantly (p=0.0014) down-
regulated one of the important costimulatory molecules, CD28
in infected cells.
The significant reduction in CD28 expression in infected T
cells, caused by HIV-1 Vpr prompted us to measure the effect
of Vpr on the expression of its counter regulator molecule
CTLA-4. Unlike the constitutively expressed CD28, CTLA-4
is expressed only upon activation and mainly resides in
intracytoplasmic vesicles, and then recruited to the immuno-
logical synapse to regulate signal transduction (Egen and
Allison, 2002). To evaluate the effect of Vpr on the expre-
ssion of CTLA-4, both cell surface and intracellular CTLA-4
were stained and assessed in PBL from the same donor by
flow cytometry using similar gating as shown in Fig. 1A. Fig.
1D indicates that presence of Vpr increased expression of
CTLA-4 in the infected cells. Cells expressing CTLA-4 are
30.6% in HIV-1 vpr(+)/EGFP-virus-infected culture, whereas,
only 18% of HIV-1 vpr(−)/EGFP-virus-infected cells
expressed the inhibitory costimulatory molecule, CTLA-4.
Similar results were observed in multiple donors (N=7), asFig. 2. Effect of HIV-1 Vpr on CD25 and HLA-DR in infected and bystander cells
methods. Four days post infection, the cell surface expression of CD25, and HLA-D
Fig. 1A. Expression of CD25 and HLA-DR was analyzed in infected (EGFP+) and b
donors. (B) Dot plot represents data from four donors.shown in Fig. 1E (p=0.026), further indicating that the
observed increase in CTLA-4 expression is Vpr specific and
not donor-dependent.
Next, to rule out the possibility that HIV-1 Vpr did not alter
the expression of T cell receptors globally, surface expression of
CD25 and HLA-DR molecules was measured within the
infected and uninfected population using the same donor cells
(Fig. 2). There is no significant change in the surface expression
of CD25 and HLA-DR molecules in the presence or absence of
Vpr, in both the infected as well as the bystander cells. Similar
results were observed in multiple donors (Fig. 2). These results
indicate that the dysregulation of CD28 and CTLA-4 shown
above is specifically regulated by the vpr gene product. A
decrease in CD28, the positive regulator of the signal
transduction, combined with an increase in negative regulator,
CTLA-4 can have an additive effect to impair proximal signal
transduction following the recognition of specific antigen by the
T cell receptor (Rudd et al., 2002; Saito and Yamasaki, 2003).
HIV-1 Vpr inhibits interferon gamma (IFN-γ) secretion in
infected T cells
Interferon gamma is one of the key Th1 cytokines secreted
by T lymphocytes upon activation and is required for antiviral
immunity. It has been well documented that there is a decline
in the IFN-γ secreting cell population during HIV-1 infection,
and this correlates with the compromised T-cell-mediated
response in patients (Boaz et al., 2002; Nicastri et al., 1999;
Onlamoon et al., 2004). Hence we evaluated the amount of: PBL were infected with EGFP reporter viruses as described in Materials and
R was analyzed by flow cytometry. Viable lymphocytes were gated as shown in
ystander (EGFP−) cells. (A) Representative contour plot for one of the multiple
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HIV-1 vpr(−)/EGFP virus by ELISA on days 3 and 6 post
infection to further delineate the potential implications of Vpr.
Results indicate that in the presence of Vpr there is a
significant decrease (>50%) in IFN-γ production compared to
Vpr-negative virus-infected culture on day 6 post infection
(Fig. 3A). These results were consistent in multiple donors
(N=4), as depicted in Fig. 3B.
To further quantitate the level of IFN-γ production within the
infected cells, intracellular staining for IFN-γ was performed.
Number of infected cells that are positive for intracellular IFN-γ
was threefold lower in HIV-1 vpr(+)/EGFP-virus-infected
culture compared to that in HIV-1 vpr(−)/EGFP-virus-infected
culture. In case of HIV-1 vpr(+)/EGFP-infected cells, onlyFig. 3. HIV-1 Vpr inhibits IFN-γ production in HIV-1-infected lymphocytes: (A) PB
(−)/EGFP as described in Materials and methods. The supernatant collected 3 and 6 d
denote the standard error of the mean, obtained from samples in triplicates. (B) Produ
paired t test. (C) Detection of IFN-γ by intracellular staining using PE conjugated IgG
using flow cytometry. Viable lymphocytes were gated and IFN-γ production with in
histograms represents one of the multiple donors (N=4) evaluated.3.55% of cells were positive for IFN-γ, whereas 11.8% of HIV-
1 vpr(−)/EGFP-infected cells produced IFN-γ (Fig. 3C). These
data suggest that HIV-1 Vpr can mediate its inhibitory effects in
the presence of other viral proteins.
HIV-1 Vpr inhibits the nuclear translocation of the p65
member of the NF-κB family in infected cells
Results presented above indicate that HIV-1 Vpr inhibited
the production of IFN-γ in HIV-1-infected cells, suggesting that
HIV-1 Vpr not only selectively modulates the cell surface
expression of the major costimulatory molecules CD28 and
CTLA-4, but also interferes with downstream events of T cell
activation. NF-κB is one of the important cellular factors thatL were infected with the EGFP reporter virus HIV-1 vpr(+)/EGFP or HIV-1 vpr
ays post infection was assessed for IFN-γ production by ELISA. The error bars
ction of IFN-γ in multiple donors (N=4) was evaluated statistically evaluated by
1 isotype or anti-human IFN-γ antibody following fixation and permeabilization,
the infected (EGFP+) and bystander (EGFP−) lymphocytes was evaluated. The
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further evaluated the effect of HIV-1 Vpr on NF-κB transloca-
tion in infected lymphocytes by immunofluorescence to
elucidate the involvement of Vpr in the context of infection.
Results indicate that in more than 70% of HIV-1 vpr(+)/EGFP-
virus-infected lymphocytes NF-κB is localized in the cyto-
plasm, whereas in HIV-1 vpr(−)/EGFP-virus-infected cells, NF-
κB is located predominantly in the nucleus (Fig. 4A). A similar
pattern was seen in multiple donors (N=4) as shown in Fig. 4B.
Though previous studies have suggested that endogenous
expression of Vpr in the absence of other viral proteins inhibits
the transcriptional regulation of NF-κB in cell lines (Ayyavoo et
al., 1997), this is the first report indicating a similar
phenomenon in HIV-1-infected primary lymphocytes. TogetherFig. 4. Subcellular localization of NF-κB in HIV-1 vpr(+) or HIV-1 vpr(−)-virus-infe
and cytospun on to slides, and stained for p65 subunit of NF-κB protein, as descr
fluorescence of EGFP (Green), and the p65 subunit of NF-κB was detected using a po
in panel (overlay) indicate the presence of NF-κB within the infected cell. As indica
virus, and the lower panels show the cells infected with HIV-1 vpr(−)/EGFP virus. (B
cells by the absence of EGFP florescence. Subcellular distribution of NF-κB was cou
cells) for all multiple donors (N=4). The absolute cell numbers that are positive for
analysis by comparing HIV-1 vpr(+) and HIV-1 vpr(−) groups. (For interpretation o
version of this article.)these results indicate that one of the mechanism(s) exerted by
Vpr is to block NF-κB-mediated transcriptional regulation as
part of the immune evasive strategies as noted in other viruses
(Jarvis et al., 2006; Jones and Arvin, 2006).
Discussion
Effective innate and adaptive immune responses are essential
for control and elimination of viral infections. Many viruses,
including HIV-1, have evolved ways to utilize viral antigens as
a means of evading the host immune response (Bovolenta,
2004; Collins and Baltimore, 1999; Emerman and Malim,
1998). There are increasing evidences for the role of HIV-1
accessory protein Vpr to modulate immune functions. Recently,cted lymphocytes by indirect immunofluorescence: (A) Infected PBL were fixed
ibed in Materials and methods. Infected lymphocytes were detected by direct
lyclonal antibody (Red). Nuclei were identified by DAPI staining (Blue). Arrows
ted, the upper panels show the lymphocytes infected with HIV-1 vpr(+)/EGFP
) Infected cells were identified by presence of EGFP florescence and bystander
nted within the EGFP-positive and EGFP-negative cells in ten random fields (30
NF-κB nuclear localization is presented. p value was derived using paired t test
f the references to colour in this figure legend, the reader is referred to the web
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dendritic cells and subsequently dysregulated the activation and
function of T cells (Majumder et al., 2005; Muthumani et al.,
2005). Despite the role of Vpr in inducing T cell apoptosis
(Conti et al., 2000; Muthumani et al., 2002; Stewart et al.,
1997), it is unknown whether Vpr exerts immune dysfunction in
infected T cells. Here, we have evaluated the direct effect of Vpr
on T cell function independent of any interaction with infected
APCs, using PBL and EGFP reporter containing X4 tropic
(pNL43) HIV-1 vpr(+) and HIV-1 vpr(−) viruses.
The costimulatory molecules CD28 and CTLA-4 are the
major players regulating the proximal TCR signaling events.
Dysregulation of CD28 and CTLA-4 on both CD4+ and CD8+
lymphocytes has been well documented in HIV-1-infected
patients and is related to progression of the disease (Leng et
al., 2002; Riley et al., 2000; Speth and Dierich, 1999; Stone et
al., 2005), and HIV-1 accessory proteins selectively regulate
this process (Speth and Dierich, 1999). Our results indicate
that Vpr differentially modulated CD28 and CTLA-4 mole-
cules in infected T cells, in the presence of Nef and other viral
proteins, indicating that HIV-1 proteins might function in an
additive manner. The selective nature of Vpr-mediated down-
regulation is further supported by the observation that under
similar conditions (same time points) Vpr did not affect the
surface expression of CD25 or HLA-DR. This suggests that
the differences seen in the expression level of CD28 and
CTLA-4, in the presence of HIV-1 Vpr, are very specific and
not due to global changes in the expression of cellular
molecules or differences in the activation status of the infected
lymphocytes. We next delineated the defect in downstream
effector function (measured by IFN-γ production) in infected
cells as an outcome of Vpr-mediated differential regulation of
CD28 and CTLA-4. HIV proteins Env, Tat and Nef have been
shown to directly activate some of the downstream factors, but
most of these studies have been conducted using recombinant
viral proteins, and the effects in the context of infection is
limited (Speth and Dierich, 1999). Next we assessed the effect
of Vpr on downstream effector molecule, IFN-γ in these
cultures. HIV-1 Vpr not only reduced IFN-γ production in
infected culture, it also further blocked the stimulation by
potent stimulators, such as PMA and ionomycin that bypass
the proximal signaling events and directly activate the
downstream signaling factors (Gilmore and Martin, 1983;
Truneh et al., 1985). This clearly suggests that HIV-1 Vpr not
only interferes with the proximal signaling in T cells, but also
has additional inhibitory effects on the downstream effector
molecules.
NF-κB is one of the major downstream factors involved in
the regulation of IFN-γ secretion upon TCR signaling (Li-
Weber et al., 2005). HIV-1 Vpr has been reported to both
activate and inhibit NF-κB-mediated downstream effects,
depending on the cellular context, Vpr forms present and
activation status of the cells (Ayyavoo et al., 1997; Varin et al.,
2005). In our current study, we have shown that Vpr inhibited
the nuclear translocation of the p65 subunit of NF-κB.
Activated NF-κB is required for antiviral effects. Collectively,
the results presented in this study delineate the role of HIV-1Vpr in the regulation of T lymphocyte function in the context
of infection mainly by altering the level of proximal TCR
signaling, as evident by downregulation of CD28 and
upregulation of CTLA-4, and by blocking distal events (IFN-
γ production) at the transcriptional level independently. These
events initiated early during infection could not be reversed by
restimulation as observed in PMA/ionomycin activation,
suggesting that Vpr-mediated immune defects are not
completely reversible. The observed Vpr-mediated inhibition
of NF-κB translocation coupled with functional impairment of
T cell IFN-γ production could preferentially induce an
immunosuppressive phenotype of infected T lymphocytes.
Collectively, the results presented here delineate a role for
HIV-1 Vpr in modulating the function of T lymphocytes
during early stages of infection. Thus, HIV-1 Vpr might
potentially utilize multiple mechanism(s) to evade the immune
system, and the viral proteins could act in a coordinated
manner to impair immune activation. Identifying the mechan-
ism(s) involved in Vpr-mediated immune regulation will
improve our understanding of viral function, and assist in the
development of immunotherapeutics and antiviral strategies for
HIV-1-infected individuals.
Materials and methods
Isolation and culture of lymphocytes
Peripheral blood mononuclear cells (PBMC) were isolated
from heparinized blood obtained from healthy donors using
Ficoll-Hypaque gradient centrifugation. CD14 depleted lym-
phocytes were purified by negative selection using anti-CD14
monoclonal antibody-coated magnetic microbeads (Miltenyi
Biotech, Auburn, CA) as described previously (Majumder et al.,
2005). Briefly, PBMC were resuspended in MACS buffer
(2 mM EDTA, 0.05% bovine serum albumin in phosphate-
buffered saline [PBS]) and incubated with anti-CD14 MACS
beads at 4 °C for 15 min. Cells were washed with MACS buffer
and resuspended in MACS buffer before passing through a
magnetic column. The flow through was collected, and the
purity of the lymphocytes was tested by flow cytometry using
CD14-phycoerythrin (PE) (BD-Pharmingen, San Diego, CA)
and CD3-ECD (Beckman Coulter, Miami, FL). More than 95%
of isolated cells were CD14− (data not shown). PBL (1×107/
ml) were stimulated with anti-CD3 (OKT3) antibody (10 μg/
ml)-coated flasks along with soluble anti-CD28 antibody (BD
Pharmingen clone 28.2) (1 μg/ml) for 3 days as described
(Levine et al., 1998) and cultured in RPMI 1640 supplemented
with 10% fetal bovine serum (FBS) and 1× penicillin/
streptomycin and rIL-2 (5 U/ml).
Construction of HIV-1wt and HIV-1Δvpr EGFP reporter
proviral plasmids
To evaluate the effects of Vpr in productively infected cells,
we constructed EGFP reporter viruses, expressing full-length
Vpr protein (HIV-1 vpr(+)/EGFP) and the other which does not
express Vpr (HIV-1 vpr(−)/EGFP). An Internal Ribosomal
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maintain the expression of Nef (Fig. S1A). The vpr gene open
reading frame in HIV-1 vpr(−)/EGFP virus has mutation at
nucleotide 56, resulting in no detectable Vpr expression as
shown byWestern blot. The integrity of the viral DNA sequence
was confirmed by sequencing, and the expression of viral
proteins Gag, Vpr and Nef were confirmed by Western blot and/
or by functional assays.
Virus preparation and infection of T cells
HEK293 T cells (2×106 per plate) were transfected with
10 μg of HIV-1 vpr(+)/EGFP or HIV-1 vpr(−)/EGFP proviral
construct by calcium phosphate precipitation method (Majum-
der et al., 2005). Forty-eight hours posttransfection, the
supernatants were collected, filtered through a 0.4-μm filter to
remove cellular debris, and centrifuged at 22,000 rpm for 1 h.
The virus pellets were resuspended in PBS and stored in
aliquots at −80 °C for subsequent assays. Virus titers were
measured by p24 enzyme-linked immunosorbent assay
(ELISA), and multiplicity of infection (MOI) was calculated
by TZM blue assay using the HIV-1 reporter cell line cMAGI
(AIDS Research and Reference Reagent Program [RRRP],
National Institutes of Health [NIH]). PBL were infected with the
HIV-1 vpr(+)/EGFP or HIV-1 vpr(−)/EGFP reporter virus at a
MOI of 0.01. Six hours post infection, the viruses were removed
by washing, and cells were maintained in R10 media containing
rIL-2 (5 U/ml).
Flow cytometry
To confirm the purity of lymphocytes, we tested the
phenotype of the cells by flow cytometry. Cells were stained
with CD14-PE and CD3-ECD or with a corresponding
fluorochrome-conjugated IgG isotype control. Expression of
costimulatory and other surface markers were evaluated by
flow cytometry. Surface staining was performed for CD28,
whereas for CTLA-4, both surface and intracellular staining
was performed. Briefly, at indicated time points cells were
washed twice with cold PBS (pH 7.2) containing 10% FBS
and incubated with respective fluorochrome conjugated anti-
body or isotype control for 1 h at 4 °C. The cells were washed
three times with fluorescence-activated cell sorter (FACS)
buffer. For the detection of intracellular proteins, fixation and
permeabilization were carried out using the CytoFix-CytoPerm
kit (BD-Bioscience, Mountainview, CA). The cells were fixed
in the BD CytoFix-Cytoperm solution for 20 min, followed by
two washes with Perm-Wash buffer (BD-Bioscience). Intra-
cellular staining was performed at room temperature for 1 h
using the recommended dilution of antibody, per 106 cells,
followed by two washes in Perm-Wash buffer and analyzed by
flow cytometry. Gating was done as described below. Firstly,
live lymphocytes were gated based on Side scatter and
Forward scatter. Based on this, CD3+ cells were gated to
eliminate the CD3− population (NK cells), and then infected
and uninfected (bystander) cells were identified based on the
expression of EGFP within the CD3+ population. Intracellularcytokine staining was carried out following the standard
staining protocol. Cells (1×106) at the mentioned time point
were stimulated with PMA (100 ng/ml) and ionomycin (1 μg/
ml) in the presence of GolgiStop (2 μl/ml) for a duration of
8 h, followed by incubation at 4 °C for 6 h. Intracellular
staining was done with IFN-γ or IgG1 isotype control using
the same protocol as described above. Samples were analyzed
using Epics-XL (Beckman Coulter, Miami, FL) with minimum
of 20,000 gated events acquired for each sample, and the mean
fluorescence intensity (MFI) was calculated using Cell Quest
and Flow Jo software.
Western blotting
Lymphocytes were cultured and infected as described above
for 3 days. A total of 5×106 uninfected and infected
lymphocytes were washed twice with PBS and lysed in RIPA
buffer containing 50 mM Tris (pH 7.5), 150 mM NaCl, 1%
Triton X-100, 1 mM sodium orthovanadate, 10 mM sodium
fluoride, 1.0 mM phenylmethylsulfonyl fluoride, 0.05%
deoxycholate, 10% sodium dodecyl sulfate, aprotinin (0.07
trypsin inhibitor unit/ml), and the protease inhibitors leupeptin,
chymostatin, and pepstatin (1 μg/ml; Sigma). Cell lysates were
clarified by centrifugation, and total cell lysates (50 μg) were
separated on a 10.5 to 12% sodium dodecyl sulfate-polyacry-
lamide gel (SDS-PAGE) electrophoresis gel, transferred, and
immunoblotted with anti-HIV-1 p24, anti-HIV-1 Nef (AIDS
RRRP, NIH), and anti-HIV-1 Vpr (a kind gift from John
Kappes, University of Alabama) antibodies. Tubulin was used
as loading control. The blots were developed using an ECL kit
(Amersham Biosciences, Piscataway, NJ).
Immunofluorescence
Forty-eight hours post infection, lymphocytes were washed
with PBS, and attached onto slides using cytospin. Cells were
fixed using in 3.7% formaldehyde at room temperature for
10 min, washed and permeabilized with 0.5% Triton X-100 for
an additional 10 min. After washing 3 times with PBS, cells
were blocked with 5% BSA at room temperature for 1 h
followed by incubation with primary antibody (NF-κB (p65)
(1:200 dilution, Santa Cruz)) for 1 h at room temperature. Cells
were washed 3 times with 1× PBS, and incubated with goat
anti-rabbit IgG Rhodamine (RRX) (1:400; Jackson ImmunoR-
esearch, West Grove, PA) for 1 h at room temperature.
Following three washes with 1× PBS, cells were mounted with
VECTASHIELD mounting media containing DAPI (Vector
Laboratories, Burlingame, CA). Immunofluorescence was
detected using a fluorescence microscope with Nikon SPOT
camera (Fryer, Huntley, IL) and images were processed using
MetaMorph software (Universal Imaging Corporation, Dow-
nington, PA).
IFN-γ ELISA
Following infection of PBL with HIV-1 vpr(+)/EGFP or
HIV-1 vpr(−)/EGFP, supernatants were collected and analyzed
355N.J. Venkatachari et al. / Virology 358 (2007) 347–356for the presence of IFN-γ. INF-γ was measured by using Opti-
EIA enzyme-linked immunosorbent assay (ELISA) kit (BD
Biosciences, San Diego, CA) according to the manufacturer's
protocol.
Statistical analysis
The results were expressed as mean±standard error of the
mean. The data were analyzed using the Student's t test for
paired samples.
Acknowledgments
This work was supported by Public Health Service grant
AI50463 to VA from NIAID, National Institute of Health. We
thank Dr. Jeremy Martinson and Dr. Ronald Montelaro,
University of Pittsburgh for critical reading of the manuscript.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.virol.2006.08.030.
References
Aiken, C., Konner, J., Landau, N.R., Lenburg, M.E., Trono, D., 1994. Nef
induces CD4 endocytosis: requirement for a critical dileucine motif in the
membrane-proximal CD4 cytoplasmic domain. Cell 76 (5), 853–864.
Anderson, J.L., Hope, T.J., 2004. HIVaccessory proteins and surviving the host
cell. Curr. HIV/AIDS Rep. 1 (1), 47–53.
Ayyavoo, V., Mahboubi, A., Mahalingam, S., Ramalingam, R., Kudchodkar, S.,
Williams, W.V., Green, D.R., Weiner, D.B., 1997. HIV-1 Vpr suppresses
immune activation and apoptosis through regulation of nuclear factor kappa
B. Nat. Med. 3 (10), 1117–1123.
Bachand, F., Yao, X.J., Hrimech, M., Rougeau, N., Cohen, E.A., 1999.
Incorporation of Vpr into human immunodeficiency virus type 1 requires a
direct interaction with the p6 domain of the p55 gag precursor. J. Biol.
Chem. 274 (13), 9083–9091.
Boaz, M.J., Waters, A., Murad, S., Easterbrook, P.J., Vyakarnam, A., 2002.
Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4
T cell responses is associated with nonprogression in HIV-1 infection.
J. Immunol. 169 (11), 6376–6385.
Bovolenta, C., 2004. Blocking HIV-1 Vif restores a natural mechanism of
intracellular antiviral defense. Curr. Drug Targets Immune Endocr. Metabol.
Disord. 4 (4), 257–263.
Collins, K.L., Baltimore, D., 1999. HIV's evasion of the cellular immune
response. Immunol. Rev. 168, 65–74.
Conti, L., Matarrese, P., Varano, B., Gauzzi, M.C., Sato, A., Malorni, W.,
Belardelli, F., Gessani, S., 2000. Dual role of the HIV-1 vpr protein in the
modulation of the apoptotic response of T cells. J. Immunol. 165 (6),
3293–3300.
Egen, J.G., Allison, J.P., 2002. Cytotoxic T lymphocyte antigen-4 accumulation
in the immunological synapse is regulated by TCR signal strength.
Immunity 16 (1), 23–35.
Emerman, M., Malim, M.H., 1998. HIV-1 regulatory/accessory genes: keys to
unraveling viral and host cell biology. Science 280 (5371), 1880–1884.
Giannoni, F., Barnett, J., Bi, K., Samodal, R., Lanza, P., Marchese, P., Billetta,
R., Vita, R., Klein, M.R., Prakken, B., Kwok, W.W., Sercarz, E., Altman, A.,
Albani, S., 2005. Clustering of T cell ligands on artificial APC membranes
influences T cell activation and protein kinase C theta translocation to the T
cell plasma membrane. J. Immunol. 174 (6), 3204–3211.
Gilmore, T., Martin, G.S., 1983. Phorbol ester and diacylglycerol induce protein
phosphorylation at tyrosine. Nature 306 (5942), 487–490.Hrimech, M., Yao, X.J., Bachand, F., Rougeau, N., Cohen, E.A., 1999. Human
immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early
protein during HIV-1 infection. J. Virol. 73 (5), 4101–4109.
Inaba, K., Inaba, M., 2005. Antigen recognition and presentation by dendritic
cells. Int. J. Hematol. 81 (3), 181–187.
Jarvis, M.A., Borton, J.A., Keech, A.M., Wong, J., Britt, W.J., Magun, B.E.,
Nelson, J.A., 2006. Human cytomegalovirus attenuates interleukin-1{beta}
and tumor necrosis factor alpha proinflammatory signaling by inhibition of
NF-{kappa}B activation. J. Virol. 80 (11), 5588–5598.
Jeeninga, R.E., Jan, B., van der Linden, B., van den Berg, H., Berkhout, B.,
2005. Construction of a minimal HIV-1 variant that selectively replicates in
leukemic derived T-cell lines: towards a new virotherapy approach. Cancer
Res. 65 (8), 3347–3355.
Jones, J.O., Arvin, A.M., 2006. Inhibition of the NF-{kappa}B pathway by
varicella-zoster virus in vitro and in human epidermal cells in vivo. J. Virol.
80 (11), 5113–5124.
Leng, Q., Bentwich, Z., Magen, E., Kalinkovich, A., Borkow, G., 2002. CTLA-
4 upregulation during HIV infection: association with anergy and possible
target for therapeutic intervention. AIDS 16 (4), 519–529.
Levesque, K., Zhao, Y.S., Cohen, E.A., 2003. Vpu exerts a positive effect on
HIV-1 infectivity by down-modulating CD4 receptor molecules at the
surface of HIV-1-producing cells. J. Biol. Chem. 278 (30), 28346–28353.
Levine, B.L., Cotte, J., Small, C.C., Carroll, R.G., Riley, J.L., Bernstein, W.B.,
Van Epps, D.E., Hardwick, R.A., June, C.H., 1998. Large-scale production
of CD4+ Tcells from HIV-1-infected donors after CD3/CD28 costimulation.
J. Hematother. 7 (5), 437–448.
Levy, D.N., Refaeli, Y., Weiner, D.B., 1995. Extracellular Vpr protein increases
cellular permissiveness to human immunodeficiency virus replication and
reactivates virus from latency. J. Virol. 69 (2), 1243–1252.
Li, L., Li, H.S., Pauza, C.D., Bukrinsky, M., Zhao, R.Y., 2005. Roles of HIV-1
auxiliary proteins in viral pathogenesis and host-pathogen interactions. Cell
Res. 15 (11–12), 923–934.
Li-Weber, M., Treiber, M.K., Giaisi, M., Palfi, K., Stephan, N., Parg, S.,
Krammer, P.H., 2005. Ultraviolet irradiation suppresses T cell activation
via blocking TCR-mediated ERK and NF-kappa B signaling pathways.
J. Immunol. 175 (4), 2132–2143.
Lum, J.J., Cohen, O.J., Nie, Z., Weaver, J.G., Gomez, T.S., Yao, X.J., Lynch, D.,
Pilon, A.A., Hawley, N., Kim, J.E., Chen, Z., Montpetit, M., Sanchez-
Dardon, J., Cohen, E.A., Badley, A.D., 2003. Vpr R77Q is associated with
long-term nonprogressive HIV infection and impaired induction of
apoptosis. J. Clin. Invest. 111 (10), 1547–1554.
Magott-Procelewska, M., 2004. Costimulatory pathways as a basic mecha-
nisms of activating a tolerance signal in T cells. Ann. Transplant 9 (3),
13–18.
Majumder, B., Janket, M.L., Schafer, E.A., Schaubert, K., Huang, X.L., Kan-
Mitchell, J., Rinaldo Jr., C.R., Ayyavoo, V., 2005. Human immunodeficiency
virus type 1 Vpr impairs dendritic cell maturation and T-cell activation:
implications for viral immune escape. J. Virol. 79 (13), 7990–8003.
Melief, C.J., 2003. Mini-review: regulation of cytotoxic T lymphocyte
responses by dendritic cells: peaceful coexistence of cross-priming and
direct priming? Eur. J. Immunol. 33 (10), 2645–2654.
Muthumani, K., Hwang, D.S., Desai, B.M., Zhang, D., Dayes, N., Green, D.R.,
Weiner, D.B., 2002. HIV-1 Vpr induces apoptosis through caspase 9 in T
cells and peripheral blood mononuclear cells. J. Biol. Chem. 277 (40),
37820–37831.
Muthumani, K., Hwang, D.S., Choo, A.Y., Mayilvahanan, S., Dayes, N.S.,
Thieu, K.P., Weiner, D.B., 2005. HIV-1 Vpr inhibits the maturation and
activation of macrophages and dendritic cells in vitro. Int. Immunol. 17 (2),
103–116.
Nicastri, E., Sarmati, L., Ercoli, L., Mancino, G., D'Ambrosio, E., d'Ettorre, G.,
Mastroianni, C.M., Vullo, V., Andreoni, M., 1999. Reduction of IFN-gamma
and IL-2 production by peripheral lymphocytes of HIV-exposed seronega-
tive subjects. AIDS 13 (11), 1333–1336.
Oh, S., Hodge, J.W., Ahlers, J.D., Burke, D.S., Schlom, J., Berzofsky, J.A.,
2003. Selective induction of high avidity CTL by altering the balance of
signals from APC. J. Immunol. 170 (5), 2523–2530.
Onlamoon, N., Pattanapanyasat, K., Ansari, A.A., 2004. Impaired IFN-gamma
production by viral immunodominant peptide-specific tetramer+ CD8+ T
356 N.J. Venkatachari et al. / Virology 358 (2007) 347–356cells in HIV-1 infected patients is not secondary to HAART. Clin. Dev.
Immunol. 11 (3–4), 287–298.
Perkins, D., Wang, Z., Donovan, C., He, H., Mark, D., Guan, G., Wang, Y.,
Walunas, T., Bluestone, J., Listman, J., Finn, P.W., 1996. Regulation of
CTLA-4 expression during T cell activation. J. Immunol. 156 (11),
4154–4159.
Riley, J.L., June, C.H., 2005. The CD28 family: a T-cell rheostat for therapeutic
control of T-cell activation. Blood 105 (1), 13–21.
Riley, J.L., Schlienger, K., Blair, P.J., Carreno, B., Craighead, N., Kim, D.,
Carroll, R.G., June, C.H., 2000. Modulation of susceptibility to HIV-1
infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule.
J. Exp. Med. 191 (11), 1987–1997.
Rudd, C.E., Martin, M., Schneider, H., 2002. CTLA-4 negative signaling via
lipid rafts: a new perspective. Sci. STKE 2002 (128), PE18.
Saito, T., Yamasaki, S., 2003. Negative feedback of T cell activation through
inhibitory adapters and costimulatory receptors. Immunol. Rev. 192,
143–160.
Saksena, N.K., Ge, Y.C., Wang, B., Xiang, S.H., Dwyer, D.E., Randle, C.,
Palasanthiran, P., Ziegler, J., Cunningham, A.L., 1996. An HIV-1 infected
long-term non-progressor (LTNP): molecular analysis of HIV-1 strains in the
vpr and nef genes. Ann. Acad. Med. Singapore 25 (6), 848–854.
Speth, C., Dierich, M.P., 1999. Modulation of cell surface protein expression by
infection with HIV-1. Leukemia. 13 (Suppl. 1), S99–S105.
Steiner, K., Waase, I., Rau, T., Dietrich, M., Fleischer, B., Broker, B.M., 1999.
Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV
infection. Clin. Exp. Immunol. 115 (3), 451–457.
Stewart, S.A., Poon, B., Jowett, J.B., Chen, I.S., 1997. Human immunodefi-
ciency virus type 1 Vpr induces apoptosis following cell cycle arrest. J. Virol.
71 (7), 5579–5592.
Stone, S.F., Price, P., French, M.A., 2005. Dysregulation of CD28 and CTLA-4
expression by CD4 T cells from previously immunodeficient HIV-infectedpatients with sustained virological responses to highly active antiretroviral
therapy. HIV Med. 6 (4), 278–283.
Stove, V., Van de Walle, I., Naessens, E., Coene, E., Stove, C., Plum, J.,
Verhasselt, B., 2005. Human immunodeficiency virus Nef induces rapid
internalization of the T-cell coreceptor CD8alphabeta. J. Virol. 79 (17),
11422–11433.
Truneh, A., Albert, F., Golstein, P., Schmitt-Verhulst, A.M., 1985. Calcium
ionophore plus phorbol ester can substitute for antigen in the induction of
cytolytic T lymphocytes from specifically primed precursors. J. Immunol.
135 (4), 2262–2267.
Tungaturthi, P.K., Sawaya, B.E., Singh, S.P., Tomkowicz, B., Ayyavoo, V.,
Khalili, K., Collman, R.G., Amini, S., Srinivasan, A., 2003. Role of HIV-1
Vpr in AIDS pathogenesis: relevance and implications of intravirion,
intracellular and free Vpr. Biomed. Pharmacother. 57 (1), 20–24.
Varin, A., Decrion, A.Z., Sabbah, E., Quivy, V., Sire, J., Van Lint, C., Roques,
B.P., Aggarwal, B.B., Herbein, G., 2005. Synthetic Vpr protein activates
activator protein-1, c-Jun N-terminal kinase, and NF-kappaB and stimu-
lates HIV-1 transcription in promonocytic cells and primary macrophages.
J. Biol. Chem. 280 (52), 42557–42567.
Wang, B., Ge, Y.C., Palasanthiran, P., Xiang, S.H., Ziegler, J., Dwyer, D.E.,
Randle, C., Dowton, D., Cunningham, A., Saksena, N.K., 1996. Gene
defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term
nonprogressing mother and child pair: in vivo evolution of vpr quasispecies
in blood and plasma. Virology 223 (1), 224–232.
Willey, R.L., Maldarelli, F., Martin, M.A., Strebel, K., 1992. Human
immunodeficiency virus type 1 Vpu protein induces rapid degradation of
CD4. J. Virol. 66 (12), 7193–7200.
Williams, M., Roeth, J.F., Kasper, M.R., Fleis, R.I., Przybycin, C.G., Collins,
K.L., 2002. Direct binding of human immunodeficiency virus type 1 Nef to
the major histocompatibility complex class I (MHC-I) cytoplasmic tail
disrupts MHC-I trafficking. J. Virol. 76 (23), 12173–12184.
